CI_with has_Ingredient has_MoA has_PE may_prevent may_treat drug associated with AE in adult used to treat disease Lipoxygenase Inhibitors [MoA] Glucocorticoid Receptor Agonists [MoA] Autoimmune Diseases [Disease/Finding] Drug Hypersensitivity [Disease/Finding] Graft vs Host Disease [Disease/Finding] Hematologic Diseases [Disease/Finding] Hypersensitivity [Disease/Finding] Inflammation [Disease/Finding] Neoplasms [Disease/Finding] Neurologic Manifestations [Disease/Finding] Respiratory Distress Syndrome, Adult [Disease/Finding] Skin Diseases, Infectious [Disease/Finding] Carbohydrate Metabolism Alteration [PE] Decreased Glucocorticoid Secretion [PE] Decreased Leukotriene Activity [PE] Decreased Prostaglandin Activity [PE] Decreased Protein Synthesis [PE] Decreased Thromboxane Activity [PE] Lipid Metabolism Alteration [PE] Lysosomal Function Alteration [PE] Infant [Disease/Finding] Decreased Polymorphonuclear Leukocyte Migration [PE] Decreased Fibroblast Migration [PE] Decreased Capillary Permeability [PE] METHYLPREDNISOLONE METHYLPREDNISOLONE ACETATE http://www.accessdata.fda.gov/drugsatfda_docs/anda/98/40183_Methylprednisolone_Prntlbl.pdf Active 43502P7F0P C0600901 Ingredient METHYLPREDNISOLONE ACETATE 4018070 N0000146411 <VANDF_Record>50.416^667^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>667</VA_IEN> 155323 methylprednisolone acetate C17200 methylprednisolone acetate [Chemical/Ingredient] rheumatic disease convulsion AE muscular weakness AE headache AE hypertension AE vertigo AE cataract AE duodenal ulcer AE sodium retention AE fluid retention AE